Updates are available Erratum dated 2015-09-30
Click to view Erratum: https://doi.org/10.1038/nrn4039
-
Authors
Elgoyhen, Ana Belén
Langguth, Berthold
De Ridder, Dirk
Vanneste, Sven
- License Information
-
More Information
Article History
First Online: 16 September 2015
Competing interests
: A.B.E. has received research funding from Merz. B.L. received honoraria for speaking and consultancy from Advanced Neuro Modulation, AstraZeneca, Autifony, Gerson Lehrman Group, Lundbeck, McKinsey, Merz, Magventure, Novartis, Neuromod Devices, Pfizer and Servier; received research funding from AstraZeneca, Cerbomed, Deymed, Magventure, Siemens and Otonomy; received travel and accommodation payments from the European Union (European Cooperation in Science and Technology (COST)), Lilly, Servier and Pfizer; and holds patents for the use of neuronavigation for transcranial magnetic stimulation in the treatment of tinnitus. D.D.R. has received speaker's fees, travel and accommodation payments and research funding from St Jude Medical and holds intellectual property rights to different neurostimulation designs for implanted electrodes. A.B.E., B.L. and D.D.R. hold a patent for the use of cyclobenzaprine in tinnitus treatment. S.V. declares no competing interests.
